Skip to main content

Table 2 Stratified analysis of the HRs of overall survival

From: Prognostic and clinicopathologic significance of circZFR in multiple human cancers

Subgroups

No. of studies

No. of patients

HR (95% CI)

Model

Heterogeneity

I2 (%)

p value

1 Sample size

 1.1 ≥ 60

7

499

1.90 (1.47, 2.45)

Fixed

31.6

0.187

 1.2< 60

4

190

2.73 (1.90, 3.91)

Fixed

0.00

0.760

2 Cancer type

 2.1 BlC

3

219

2.41 (1.59, 3.66)

Random

0.00

0.895

 2.2 BrC

2

135

1.43 (0.54, 3.79)

Random

78.9

0.030

 2.3 HCC

3

190

2.38 (1.66, 3.40)

Random

0.00

0.644

 2.4 Others

3

145

2.65 (1.63, 4.29)

Random

0.00

0.608

3 Follow-up

 3.1 ≥ 60

10

624

2.44 (1.95, 3.05)

Fixed

0.00

0.987

 3.2< 60

1

65

1.38 (0.57, 3.33)

Fixed

–

–

4 Cut-off value

 4.1 Mean

1

80

2.05 (1.01, 4.16)

Fixed

–

–

 4.2 Median

5

344

2.38 (1.77, 3.20)

Fixed

0.00

0.826

 4.3 N/A

5

265

2.39 (1.73, 3.29)

Fixed

0.00

0.848

  1. BlC bladder cancer, BrC breast cancer, CI confidence interval, HCC hepatocellular carcinoma, HR hazard ratio, N/A not available